Revenue Performance - Revenue for Q3 2025 was $1,757,094, representing a 23% increase compared to $1,433,151 in Q3 2024[5] - Consolidated clinic revenue increased by 21% to $1,722,223 from $1,418,011[5] - Total revenue from all clinics, including consolidated and equity method clinics, was $1,995,007, an 18% increase from $1,686,093[5] Financial Losses - The net loss for Q3 2025 was $(2.6) million, compared to $(1.6) million in Q3 2024[5] - Adjusted EBITDA for Q3 2025 was $(947,568), slightly worse than $(945,949) in the prior year[5] Growth and Expansion - The company achieved 23% organic growth driven by increased patient flow and expanded telehealth capabilities[5] - INVOcell device revenue grew by 130% year-over-year due to expanded training support and improved pricing[5] - The company is pursuing an acquisition strategy with a growing pipeline of fertility clinics interested in joining INVO Fertility[5] Policy and Operational Improvements - Recent policy updates allow employers to offer standalone infertility benefit packages, expanding access to IVF coverage[5] - The company is focused on improving operational efficiencies, including a partnership with Heidi Health to integrate an AI-powered scribe platform[5]
INVO BioScience(INVO) - 2025 Q3 - Quarterly Results